wealth_bakery

VM is getting rerated after PEA valued at $344M

TSXV:VM   VOYAGEUR PHARMACEUTICALS LTD
Voyageur Pharmaceuticals Announces IRR of 137% and NPV of $344 Million from Preliminary Economic Assessment for the Frances Creek Pharmaceutical Barium Project

News Release – Calgary, Alberta - TheNewswire – January 11, 2022 - Voyageur Pharmaceuticals Ltd. (“Voyageur” or the “Company”) (TSXV:VM) is pleased to announce the results of its Preliminary Economic Assessment (“PEA”) for the development of its Frances Creek pharmaceutical barium sulfate project (the “Project”), located in British Columbia, Canada. The PEA was prepared by SGS Geological Services (“SGS”). The effective date of the PEA is January 11, 2022 and a technical report relating to the PEA will be filed on SEDAR within 45 days of this news release. All values are in Canadian dollars.

The base case economics for the Project, indicates a pre-tax net present value (“NPV”) of $464 million CAD and internal rate of return (“IRR”) of 168%, while the post tax NPV is $344 million CAD with an IRR of 137% at a discount rate of 8%. The Project assumes a pre-production period of 2 years for equipment delivery and installation, and mine permitting. The payback period under the base case is 11 months.

Based on current shares issued and outstanding, the NPV after tax = $3.38 per share (fully diluted share value = $2.59 per share).

면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.